Ask AI

Bridging Discoveries to Practice: CCO's Conference to Clinic Highlights From the 2025 ASH Annual Meeting *

Review certified expert analysis text modules, podcasts, and Capsule Summaries highlighting key studies from the 2025 ASH annual meeting.

Share

Program Content

1 Capsule Summaries

Activities

SAVE Trial
SAVE: Phase I/II Study of Oral Revumenib Plus Decitabine/Cedazuridine and Venetoclax in Cohort of Patients with Newly Diagnosed AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

*Decera Clinical Education is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.